Drugs in the Pipeline
GTx Incorporated announced top line results of its Phase 3 trial evaluating toremifene 20mg for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia (PIN), a premalignant lesion of the prostate.
Drugs in the Pipeline
CytRx Corporation announced plans to initiate a Phase 2 trial in the second half of 2010 to evaluate the effectiveness and safety of its drug candidate bafetinib (formerly known as INNO-406) in patients with an advanced form of prostate cancer known as metastatic hormone-refractory prostate cancer.
Drugs in the Pipeline
Bayer Healthcare announced that the FDA has accepted its New Drug Application (NDA) for filing and has granted priority review of Radium Ra 223 Dichloride (radium-223) for the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases.
Drugs in the Pipeline
Centocor Ortho Biotech has submitted a New Drug Application (NDA) to the FDA for abiraterone acetate administered with prednisone for the treatment of metastatic advanced prostate cancer in patients who have received prior chemotherapy containing a taxane.
Drugs in the Pipeline
Adamis Pharmaceuticals announced that it has submitted an Investigational New Drug application to the FDA for APC-100 for the treatment of prostate cancer.
Drugs in the Pipeline
Tokai Pharmaceuticals announced that galeterone (TOK-001) has received Fast Track designation from the FDA for the potential treatment of metastatic castration-resistant prostate cancer (CRPC).
Drugs in the Pipeline
Ferring Pharmaceuticals announced the launch of a Phase 3b clinical trial of degarelix (gonadotropin-releasing hormone receptor antagonist) for injection as an intermittent androgen deprivation therapy (IADT) in patients with advanced prostate cancer.
Drugs in the Pipeline
OncoGenex announced the initiation of a Phase 2 trial of OGX-427 in men with metastatic prostate cancer.
Drugs in the Pipeline
The FDA has accepted a supplemental New Drug Application for Xtandi (enzalutamide; Astellas Pharma), that aims to expand the treatment indication to men with metastatic hormone-sensitive prostate cancer.
Drugs in the Pipeline
Astellas Pharma and Medivation announced topline results from the Phase 2 STRIVE trial comparing enzalutamide with bicalutamide in men with non-metastatic or metastatic castration-resistant prostate cancer.
